Zihao Hua

USPTO Granted Patents = 11 (Patent Applications = 3)

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 13.5

ph-index = 3

Forward Citations = 77(Granted Patents)

Location History:

Tewksbury, CA (US) (2011)
Tewksbury, MA (US) (2010 - 2014)
Andover, MA (US) (2015 - 2022)

Company Filing History:

Teijin Pharma Limited

patents

1 out of 512

Sloan-kettering Institute for Cancer Research

patents

where one patent can have more than one assignee

Years Active: 2010-2022

where 'Filed Patents' based on already Granted Patents

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11332459 - Benzimidazole derivatives and their uses (2022-05-17),

2. 9556135 - Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use (2017-01-31),

3. 9505749 - Quinazolinone compounds and derivatives thereof (2016-11-29),

4. 9365522 - Pyrazole amide derivative (2016-06-14),

5. 9340549 - Oxazolidinone compounds and derivatives thereof (2016-05-17),

6. 9309263 - Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof (2016-04-12),

7. 9096615 - Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof (2015-08-04),

8. 8754192 - Compositions comprising homogeneously glycosylated erythropoietin (2014-06-17),

9. 8426447 - Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use (2013-04-23),

10. 7981891 - Aurora kinase modulators and method of use (2011-07-19),

11. 7776857 - Aurora kinase modulators and method of use (2010-08-17),

Title: Innovator Spotlight: Zihao Hua

Introduction

Zihao Hua is an accomplished inventor based in Andover, MA, known for his contributions to pharmaceutical chemistry and biotechnology. With a remarkable portfolio of 11 patents, his work focuses primarily on compounds beneficial in the treatment of significant health conditions, including neurological disorders.

Latest Patents

Among his latest innovations, Hua has developed a series of groundbreaking patents. One of the notable patents is for "Benzimidazole derivatives and their uses," which describes inhibitors of the Transient Receptor Potential Channel 6 (TRPC6) protein activity. This invention encompasses a compound of formula (I) or a pharmaceutically acceptable salt thereof, alongside pharmaceutical compositions and methods for manufacturing these compounds.

Another significant patent is for "Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use." This invention introduces a new class of compounds aimed at modulating beta-secretase enzyme (BACE) activity. These compounds can potentially treat disorders related to Alzheimer’s disease and other cognitive impairments, providing a glimmer of hope in the fight against these debilitating conditions.

Career Highlights

Zihao Hua has had a fruitful career working with esteemed companies such as Amgen Inc. and Teijin Pharma Limited. His experience in these organizations has significantly shaped his expertise in pharmaceutical innovations.

Collaborations

Throughout his career, Hua has collaborated with a number of talented professionals, including Ryan D. White and Laurie B. Schenkel. These collaborations have fostered a dynamic exchange of ideas and innovations, enhancing the outcomes of his research and developments.

Conclusion

Zihao Hua continues to be an influential figure in the field of pharmaceutical science. His dedication to innovation, through his patents and collaborations, showcases his commitment to advancing medical science and improving the quality of life for individuals suffering from various health conditions. With a bright future ahead, his work is set to pave the way for transformative therapies.

This text is generated by artificial intelligence and may not be accurate.